J Korean Surg Soc.  2013 May;84(5):298-303.

Prevention of venous thromboembolism with enoxaparin in bariatirc surgery

• Woo HD
• Kim YJ

Abstract

PURPOSE
Venous thromboembolism (VTE) after bariatric surgery is a significant cause of morbidity and mortality. Current modalities of thromboprophylaxis include subcutaneous injection of unfractionated or low-molecular-weight heparin (LMWH), pneumatic compression, elastic stockings, and inferior vena cava filters. Despite universal agreement on the need for thromboprophylaxis, no clear consensus has been reached regarding the best regimen and treatment duration of bariatric surgery.
METHODS
From April, 2009 to December, 2011, we performed 200 bariatric surgery (191 with primary intent, 9 with revisional intent). There was no history of VTE prior to surgery. Clexane therapy was done with 4000 U SQ once daily for 2 weeks to the day before surgery. Development of VTE was assessed by direct interview, physical examination in out-patient clinic, and phone calls to patients for history taking if needed. The history taking was presented in questionnaire format. The patients were asked to state their symptoms of VTE by answering the questionnaire. The patients were followed up for a minimum of 6 months after surgery to determine the incidence of clinical VTE.
RESULTS
Two-week Clexane therapy was completed in 193 patients. Clexane was stopped in 5 due to surgical related complications (4 bleeding, 1 reoperation due to leak), in 2 due to Clexane related complications (1 epistaxis, 1 metrorrhagia). Follow-up of out-patient clinic were 68%, those who could follow up by telephone were 89%. There was no evidence of VTE.
CONCLUSION
A 2-week VTE prophylaxis regimen using LMWH is simple, effective and associated with a low incidence of complications.

Keyword

Venous thromboembolism; Bariatric surgery; Low-molecular-weight heparin

MeSH Terms

Bariatric Surgery
Collodion
Consensus
Enoxaparin
Epistaxis
Follow-Up Studies
Hemorrhage
Heparin, Low-Molecular-Weight
Humans
Incidence
Injections, Subcutaneous
Outpatients
Physical Examination
Surveys and Questionnaires
Reoperation
Stockings, Compression
Telephone
Vena Cava Filters
Venous Thromboembolism
Collodion
Enoxaparin
Heparin, Low-Molecular-Weight

Reference

1. Montoya RC, Gajra A. Current status of new anticoagulants in the management of venous thromboembolism. Adv Hematol. 2012. 2012:856341.

2. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008. 133:6 Suppl. 381S–453S.

3. Sapala JA, Wood MH, Schuhknecht MP, Sapala MA. Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. Obes Surg. 2003. 13:819–825.

4. Wu EC, Barba CA. Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. Obes Surg. 2000. 10:7–13.

5. Magee CJ, Barry J, Javed S, Macadam R, Kerrigan D. Extended thromboprophylaxis reduces incidence of postoperative venous thromboembolism in laparoscopic bariatric surgery. Surg Obes Relat Dis. 2010. 6:322–325.

6. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002. 346:975–980.

7. Barba CA, Harrington C, Loewen M. Status of venous thromboembolism prophylaxis among bariatric surgeons: have we changed our practice during the past decade? Surg Obes Relat Dis. 2009. 5:352–356.

8. Samama CM, Godier A. Perioperative deep vein thrombosis prevention: what works, what does not work and does it improve outcome? Curr Opin Anaesthesiol. 2011. 24:166–170.

9. Rocha AT, de Vasconcellos AG, da Luz Neto ER, Araujo DM, Alves ES, Lopes AA. Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obes Surg. 2006. 16:1645–1655.

10. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving exnoxaparin (PROBE) study. Obes Surg. 2005. 15:1368–1374.

11. Kalfarentzos F, Stavropoulou F, Yarmenitis S, Kehagias I, Karamesini M, Dimitrakopoulos A, et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obes Surg. 2001. 11:670–676.

12. Gonzalez QH, Tishler DS, Plata-Munoz JJ, Bondora A, Vickers SM, Leath T, et al. Incidence of clinically evident deep venous thrombosis after laparoscopic Roux-en-Y gastric bypass. Surg Endosc. 2004. 18:1082–1084.

13. Chan MM, Hamza N, Ammori BJ. Duration of surgery independently influences risk of venous thromboembolism after laparoscopic bariatric surgery. Surg Obes Relat Dis. 2013. 9:88–93.

14. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg. 2003. 90:547–548.

15. House of Commons Health Committee. The prevention of venous thromboembolism in hospitalized patients. 2005. London: The Stationery Office Ltd.;3.

16. Bazinet A, Almanric K, Brunet C, Turcotte I, Martineau J, Caron S, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005. 116:41–50.

17. Ojo P, Asiyanbola B, Valin E, Reinhold R. Post discharge prophylactic anticoagulation in gastric bypass patient-how safe? Obes Surg. 2008. 18:791–796.

18. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004. 126:3 Suppl. 188S–203S.

19. Westling A, Bergqvist D, Bostrom A, Karacagil S, Gustavsson S. Incidence of deep venous thrombosis in patients undergoing obesity surgery. World J Surg. 2002. 26:470–473.

20. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg. 2002. 12:19–24.

21. Raftopoulos I, Martindale C, Cronin A, Steinberg J. The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial. Surg Endosc. 2008. 22:2384–2391.

22. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: Findings of the prophylaxis against WE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg. 2005. 15:1368–1374.

23. Frezza EE, Chiriva-Internati M. Venous thromboembolism in morbid obesity and trauma: a review of literature. Minerva Chir. 2005. 60:391–399.